The antibody-drug conjugate (ADC) landscape is at a critical inflection point, where manufacturing complexity threatens to stifle innovation amid unprecedented market demand. With over 210 ADCs in clinical development, innovative biotechnology companies face an increasingly sophisticated challenge: managing conjugation bottlenecks, manufacturing yields, and regulatory complexity with contract development and manufacturing organizations (CDMOs) while competing against well-resourced pharmaceutical giants. Research published by Wei Huang, Ph.D., et al in Acta Pharmaceutica Sinica B reveals an innovative solution that provides one-step synthesis of glycosite-specific ADCs, achieving over 95% conjugation yields in under one hour.
Authors: Jian Zhang, MD, PharmD 1
1 BioDlink
Author: 1 Jian Zhang, Chief Operating Officer, BioDlink (corresponding author)
Key terms: ADC, antibody-drug conjugate, CDMO, contract development and manufacturing organizations, natural enzyme, Endo-S2, one-step synthesis of glycosite-specific ADCs.
Published In: ADC Review| Journal of Antibody-drug Conjugates
DOI: 10.14229/jadc.2025.12.04.001.
How to cite:
Zhang J. How CDMOs can Unlock One-step, High-Yield and Homogeneous ADC Manufacturing – J. ADC. December 4, 2025. DOI: 10.14229/jadc.2025.12.04.001.
Final Editorial Review: December 3, 2025
History:
- Original Manuscript Received: November 28, 2025
- Review results received: November 29, 2025
- Manuscript accepted for publication: December 3, 2025
- Article published online: December 4, 2025
Conflict of Interest
The author does not have any competing interests.
Featured image Unsplash © 2020 – 2025 Used with permission.
© 2025 The Authors. Used with permission.
DOI: 10.14229/jadc.2025.12.04.001.
